ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2011
Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 69 citations in OpenAlex.
- Trial
- Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma withGynecologic oncology reports · 2024Article
- Integrated Bioinformatics Investigation of Novel Biomarkers of Uterine Leiomyosarcoma Diagnosis and Outcome.Journal of personalized medicine · 2023Article
- High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
- Androgens in endometrial carcinoma: the killer or helper?Journal of endocrinological investigation · 2023Review
- Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature.Biomedicines · 2022Review
- Inter-component immunohistochemical assessment of proliferative markers in uterine carcinosarcoma.Oncology letters · 2022Article
- Review
- Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report.Gynecologic oncology reports · 2021Article
- Prognostic Value of Ki-67 Index in Patients With Endometrial Stromal Sarcoma.Frontiers in medicine · 2021Article
- Clinico-pathological features of gynecological myopericytoma: a challenging diagnosis in an exceptional location.Virchows Archiv : an international journal of pathology · 2019Article
- Review
- Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma.Virchows Archiv : an international journal of pathology · 2018Article
- Identification of key genes and pathways in uterine leiomyosarcoma through bioinformatics analysis.Oncology letters · 2018Article
- Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma.Journal of gynecologic oncology · 2018Article
- Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma.Medicine · 2018Article
- Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germlineCold Spring Harbor molecular case studies · 2017Article
- 18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma.Oncotarget · 2017Article
- Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.PLoS genetics · 2016Article
- KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine sarcomas are rare and aggressive gynecologic malignancies. In this immunohistochemical (IHC) study, expression of Ki-67, p53, CD10, CD44, desmin, smooth muscle actin, estrogen receptor α (ERα), androgen receptor (AR), progesterone receptor A (PRA), and c-kit and their influence on survival in cases of uterine carcinosarcoma (CS), leiomyosarcoma (LMS), and endometrial stromal sarcoma (ESS) were evaluated. Medical records were reviewed and data collected concerning all uterine sarcomas treated during a 12-year period at Helsinki University Central Hospital. There was sufficient histological material for IHC analysis and slide review in 67 cases. Survival analysis was performed using the Kaplan-Meier method, and median survival times with 95% confidence intervals are given. Survival in cases of LMS was statistically significantly affected by the expression of p53, ERα, and PRA. Striking differences in expression of IHC markers when comparing results with those in earlier studies were the absence of AR immunoreactivity in all uterine sarcomas and low incidence of c-kit (15%; in endometrial stromal sarcoma). None of the markers was statistically significantly associated with survival of ESS and CS patients. The expression of p53, ERα, and PRA in uterine LMS may give prognostic information concerning the behavior of the disease. Hormonal therapy could be recommended as a treatment option in cases of hormone receptor-positive LMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.